Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)

NCT05175950 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

770

Enrollment

OTHER

Sponsor class

Conditions

COVID-19 (Healthy Volunteers)

Interventions

BIOLOGICAL: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03
OTHER: Normal saline

Sponsor

Korea University Guro Hospital

Collaborators

[object Object]